# FibroGen, Inc. (KYNB)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $27M  
**Price:** $6.69

> FibroGen, Inc. is a US-based biopharmaceutical company specializing in discovering, developing, and commercializing innovative therapeutics to address serious unmet medical needs. Its lead product, Roxadustat, is an oral small molecule that inhibits hypoxia-inducible factor prolyl hydroxylase, enhancing red blood cell production to treat anemia in chronic kidney disease and chemotherapy-induced anemia. The company’s pipeline includes promising candidates like FG-3246, a first-in-class antibody-drug conjugate targeting CD46, aimed at treating metastatic castration-resistant prostate cancer and other tumors. Established in 1993 and headquartered in San Francisco, California, FibroGen collaborates with major pharmaceutical partners such as Astellas Pharma and AstraZeneca. It plays a significant role in oncology and hematology, leveraging the body's natural pathways to develop treatments for life-threatening conditions, reflecting its commitment to pioneering therapies at the forefront of cancer research.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $6M | $6M | -$45M | $183M | $45.37 |
| 2024 | $30M | $14M | -$131M | -$48M | $-12.00 |
| 2023 | $148M | $129M | -$269M | -$284M | $-2.92 |
| 2022 | $141M | $120M | -$301M | -$294M | $-3.14 |
| 2021 | $235M | $222M | -$289M | -$290M | $-3.14 |
| 2020 | $176M | $167M | -$192M | -$189M | $-2.11 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $120M | $115M | $4M | $48M | — |
| 2024 | $215M | $398M | -$184M | $50M | $73M |
| 2023 | $424M | $586M | -$162M | $114M | $138M |
| 2022 | $610M | $612M | -$1M | $156M | $80M |
| 2021 | $774M | $545M | $229M | $171M | $89M |
| 2020 | $827M | $385M | $441M | $678M | $26M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $29M | -$38,000 | -$5M |
| 2024 | -$30M | $780,000 | -$138M |
| 2023 | -$233M | -$3M | -$318M |
| 2022 | -$241M | -$4M | -$185M |
| 2021 | -$90M | -$5M | -$112M |
| 2020 | -$74M | -$4M | $78M |

Source: [CompaniesByCap](https://companiesbycap.com/company/KYNB)